Doliver Advisors LP Buys 1,917 Shares of Abbott Laboratories $ABT

by · The Cerbat Gem

Doliver Advisors LP lifted its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 14.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,343 shares of the healthcare product maker’s stock after acquiring an additional 1,917 shares during the quarter. Abbott Laboratories makes up 0.6% of Doliver Advisors LP’s holdings, making the stock its 29th biggest holding. Doliver Advisors LP’s holdings in Abbott Laboratories were worth $2,087,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in the stock. Hughes Financial Services LLC acquired a new stake in Abbott Laboratories during the first quarter worth approximately $27,000. Abound Financial LLC acquired a new stake in Abbott Laboratories during the first quarter worth approximately $28,000. Elequin Capital LP acquired a new stake in Abbott Laboratories during the first quarter worth approximately $30,000. Wormser Freres Gestion acquired a new stake in Abbott Laboratories during the fourth quarter worth approximately $32,000. Finally, JCIC Asset Management Inc. acquired a new stake in Abbott Laboratories during the first quarter worth approximately $32,000. 75.18% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Wells Fargo & Company decreased their target price on Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating for the company in a research note on Friday, July 18th. BTIG Research reduced their price objective on Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating for the company in a research note on Friday, July 18th. Mizuho raised their price objective on Abbott Laboratories from $130.00 to $140.00 and gave the company a “neutral” rating in a research note on Wednesday, July 16th. Jefferies Financial Group raised Abbott Laboratories from a “hold” rating to a “buy” rating and raised their price objective for the company from $143.00 to $145.00 in a research note on Friday, July 18th. Finally, Leerink Partnrs raised Abbott Laboratories to a “hold” rating in a research note on Monday, June 16th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $144.47.

Get Our Latest Stock Analysis on ABT

Abbott Laboratories Stock Up 1.0%

Shares of NYSE:ABT opened at $133.92 on Friday. The stock has a market cap of $233.08 billion, a price-to-earnings ratio of 16.78, a PEG ratio of 2.52 and a beta of 0.69. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. Abbott Laboratories has a 12-month low of $110.86 and a 12-month high of $141.23. The business’s 50 day moving average is $130.41 and its 200 day moving average is $131.32.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting analysts’ consensus estimates of $1.26. The business had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.Abbott Laboratories’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period last year, the company posted $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, sell-side analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Insider Activity

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the business’s stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the sale, the chief financial officer directly owned 51,003 shares in the company, valued at $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories Profile

(Free Report)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Recommended Stories

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).